Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Return on Capital Employed (2016 - 2017)

Historic Return on Capital Employed for Soleno Therapeutics (SLNO) over the last 4 years, with Q4 2017 value amounting to 0.39%.

  • Soleno Therapeutics' Return on Capital Employed rose 15900.0% to 0.39% in Q4 2017 from the same period last year, while for Dec 2017 it was 0.39%, marking a year-over-year increase of 15900.0%. This contributed to the annual value of 0.36% for FY2018, which is 2300.0% up from last year.
  • Soleno Therapeutics' Return on Capital Employed amounted to 0.39% in Q4 2017, which was up 15900.0% from 0.33% recorded in Q3 2017.
  • Soleno Therapeutics' Return on Capital Employed's 5-year high stood at 2.2% during Q2 2015, with a 5-year trough of 5.25% in Q3 2015.
  • Its 4-year average for Return on Capital Employed is 1.41%, with a median of 1.37% in 2014.
  • The largest annual percentage gain for Soleno Therapeutics' Return on Capital Employed in the last 5 years was 29100bps (2016), contrasted with its biggest fall of -45800bps (2016).
  • Quarter analysis of 4 years shows Soleno Therapeutics' Return on Capital Employed stood at 1.37% in 2014, then plummeted by -94bps to 2.67% in 2015, then increased by 26bps to 1.98% in 2016, then skyrocketed by 80bps to 0.39% in 2017.
  • Its Return on Capital Employed was 0.39% in Q4 2017, compared to 0.33% in Q3 2017 and 0.27% in Q2 2017.